b GS-8374 is a potent HIV protease inhibitor (PI) with a unique diethyl-phosphonate moiety. Due to a balanced contribution of enthalpic and entropic components to its interaction with the protease (PR) active site, the compound retains activity against HIV mutants with high-level multi-PI resistance. We report here the in vitro selection and characterization of HIV variants resistant to GS-8374. While highly resistant viruses with multiple mutations in PR were isolated in the presence of control PIs, an HIV variant displaying moderate (14-fold) resistance to GS-8374 was generated only after prolonged passaging for >300 days. The isolate showed low-level cross-resistance to darunavir, atazanavir, lopinavir, and saquinavir, but not other PIs, and contained a single R41K mutation in PR combined with multiple genotypic changes in the Gag matrix, capsid, nucleocapsid, and SP2 domains. Mutations also occurred in the transframe peptide and p6* domain of the Gag-Pol polyprotein. Analysis of recombinant HIV variants indicated that mutations in Gag, but not the R41K in PR, conferred reduced susceptibility to GS-8374. The Gag mutations acted in concert, since they did not affect susceptibility when introduced individually. Analysis of viral particles revealed that the mutations rendered Gag more susceptible to PR-mediated cleavage in the presence of GS-8374. In summary, the emergence of resistance to GS-8374 involved a combination of substrate mutations without typical resistance mutations in PR. These substrate changes were distributed throughout Gag and acted in an additive manner. Thus, they are classified as primary resistance mutations indicating a unique mechanism and pathway of resistance development for GS-8374.
T he introduction of HIV protease inhibitors (PIs) into the clinic as a second class of antiretrovirals after nucleoside reverse transcriptase inhibitors started the era of combination antiretroviral therapy (ART) that halted the course of the rapidly spreading HIV epidemic in developed countries (1) (2) (3) . Since then, PIs evolved to an important class of drugs widely used in combination with other antiretrovirals in treatment-naive as well as therapyexperienced patients (4, 5) . Several pharmacologically boosted PIs including darunavir, lopinavir, and atazanavir are recommended for first-line ART in combination with tenofovir and emtricitabine (6) . The choice of PIs, particularly those approved more recently, over other classes of antiretroviral agents is at least in part driven by their higher genetic barrier for resistance development (4, 7) . Nevertheless, several large cohort studies conducted in the United States and Europe during the early 2000s have demonstrated that 20 to 45% of patients with detectable plasma viral load harbor HIV variants resistant to at least one PI (8) (9) (10) . Furthermore, transmission of resistant viruses, including strains with reduced susceptibility to approved PIs, has been documented (11, 12) , albeit with lower frequency compared to strains resistant to HIV reverse transcriptase inhibitors (13) .
The emergence of specific mutations in protease (PR) that directly decrease the inhibitor binding affinity for the enzyme active site is considered the primary mechanism of PI resistance (5) . Most peptidomimetic PIs rely on similar types of interactions with the PR active site, leading to frequent cross-resistance within this therapeutic class (14) . At least 17 major mutations have been identified in PR that affect the susceptibility of HIV to one or more PIs in a clinically relevant manner (15) . In addition, secondary (or accessory) mutations in PR are known to either enhance the resistance effect of the primary mutations or to compensate for the decrease of enzymatic activity associated with the primary mutations (16) (17) (18) . Finally, a variety of strain-and subtype-specific sequence polymorphisms exist in PR, some of which may affect the susceptibility to PIs (19, 20) .
In addition to mutations in PR itself, changes in the Gag polyprotein have also been identified in PI-resistant HIV strains (15) . These modifications occur primarily at Gag cleavage sites, improving proteolytic processing by the cognate mutant protease (21, 22) . It is believed that the majority of these changes contribute to PI resistance indirectly by increasing the viral replication capacity crippled by the PR resistance mutations (23, 24) . However, recent characterization of mutations in the NC-SP2-p6 region of Gag selected by an investigational PI, Ro-0334649, revealed their direct association with a moderate, 2-to 5-fold resistance to multiple PIs in the absence of any changes in the PR (25) . The relevance of these observations was confirmed in clinical settings (26) .
GS-8374 is a novel PI containing a unique diethyl-phosphonate moiety grafted onto a previously explored bis-tetrahydrofuran (b-THF) peptidomimetic scaffold ( Fig. 1 ) which exhibits favorable pharmacological properties, including potent in vitro activity against a wide range of HIV-1 clinical isolates and a resis-tance profile superior to approved PIs (16, 27, 28) . Initial studies have shown that the addition of the phosphonate moiety does not significantly diminish the antiretroviral potency of the parent b-THF scaffold and leads to improvement of the activity against HIV variants highly resistant to other PIs. Subsequent experiments demonstrated that this effect is at least in part due to a balanced contribution of both the enthalpic and entropic component to the interaction of GS-8374 with the HIV PR active site (16, 27) .
We explore here the genotypic and phenotypic consequences of HIV-1 replication in the presence of increasing concentrations of GS-8374. Although the virus isolate generated under the prolonged selection pressure of GS-8374 showed Ͼ10-fold reduced susceptibility to the inhibitor, only a single genotypic change in PR was detected. The mutation involved a known polymorphic residue and did not affect the phenotypic sensitivity of the virus. Instead, the isolate contained a combination of mutations in multiple domains of Gag that decreased its sensitivity to GS-8374 by improving the efficiency of polyprotein processing in the presence of the inhibitor.
MATERIALS AND METHODS
Compounds. GS-8374, (3R,3aS,6aR)-hexahydrofuro [2,3-b] furan-3-yl (2S,3R)-1-(4-((diethoxyphosphoryl)methoxy)phenyl)-3-hydroxy-4-(Nisobutyl-4-methoxyphenylsulfonamido)butan-2-ylcarbamate) (28) , and the control PIs (darunavir, saquinavir, nelfinavir, lopinavir, and amprenavir) were synthesized at Gilead Sciences. Atazanavir was isolated by reversed-phase high-pressure liquid chromatography from its therapeutic formulation (Reyataz). Zidovudine (AZT) was purchased from Sigma (St. Louis, MO).
Cells and virus. MT-2 T-lymphoblastoid cells were provided by Stanford University (Palo Alto, CA) and maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum (Irvine Scientific, Santa Ana, CA) and antibiotics. The cells were passaged twice a week and kept at densities below 800,000 cells/ml. High-titer stock of HIV-1 strain IIIB (Advanced Biotechnologies, Columbia, MD) was used as a prototype wild-type strain for the drug resistance selection experiments.
Drug resistance selection. Separate aliquots of MT-2 cells were infected with wild-type HIV-1 IIIB at a multiplicity of infection (MOI) ϭ 0.03 and incubated in six-well plates in the presence of GS-8374, atazanavir (ATV), or lopinavir (LPV). The concentration of each inhibitor used to initiate the resistance selection process corresponded to the EC 50 against the wild-type HIV-1 IIIB in MT-2 cells (3, 2, and 10 nM for GS-8374, ATV, and LPV, respectively). Untreated HIV-1-infected cells were cultured in parallel in the absence of inhibitors to control for spontaneous genetic drifts of the virus due to extensive passaging in cell culture. Infected cells were examined every 3 to 5 days, and the presence of virusinduced cytopathic effect (CPE) was visually scored (grades 0 to 4, as indicated below). If no or suboptimal CPE (grade 2 or less) was observed, cells were diluted 1:3 to 1:5 with fresh medium containing the same concentration of inhibitor. Whenever robust CPE visualized by the presence of large syncytia (scored as grade 3 or 4) was detected, several dilutions of cell-free virus (20 to 200 l of cell culture supernatant) were mixed with aliquots of fresh uninfected MT-2 cells. Newly infected cells were incubated in parallel at the same and 1.3-to 2.0-fold-higher concentrations of the inhibitor so that the virus was always cultured in the presence of at least two inhibitor concentrations in parallel. Aliquots of cell-free virus (2.0 ml) from various passages were collected and stored at Ϫ70°C for further analysis.
Genotypic analysis. Viral RNA was extracted from cell culture supernatants of virus-infected cells using a QIAamp Viral RNA minikit (Qiagen, Valencia, CA). Reverse transcription-PCR (RT-PCR) amplification was performed using the Titan One-Tube RT-PCR system (Roche Applied Sciences, Indianapolis, IN) in the presence of the primers BssHIIfor and XmaI-rev (see Table S1 in the supplemental material) under the following cycling conditions: initial incubation for 30 min at 50°C and 2 min at 95°C, followed by 40 cycles of 95°C for 30 s, 55°C for 30 s, and 68°C for 3 min. The final extension step was performed for 10 min at 68°C. Amplified DNA products were purified using QIAquick PCR purification kit (Qiagen) and sequenced using a combination of the DNA primers XmaI-rev, BssHII-for, Pro-for, E462-1, E462-4, E462-8, E462-9, E462-10, and E462-11 (see Table S1 in the supplemental material). Sequencing was performed by Elim Biopharmaceuticals (Hayward, CA) with overlapping forward and reverse primers spanning Gag amino acids 1 to 499 and protease amino acids 1 to 99.
To perform clonal sequencing of the Gag and PR genes, isolated viral RNA was amplified using the protocol described above. Amplified DNA fragments were purified by agarose gel electrophoresis and cloned into pCR-2.1 TOPO (TOPO TA cloning kit; Invitrogen, Carlsbad, CA). Colonies were screened for the correct insert size and plasmid DNA was purified from up to 22 positive clones using QIAamp DNA MiniPrep kit (Qiagen). Sequencing of cloned Gag-PR fragments was performed as described above.
Construction of recombinant viruses. Six initial targeted recombinant viruses (designated M1 to M6) were constructed by amplifying specific regions of Gag and/or PR from the final GS-8374 selected virus isolate (passage 62) and transferring them to the pLAI.2 wild-type HIV-1 proviral DNA (NIH AIDS Research and Reference Reagent Program) modified by introducing additional unique restriction sites MluI (90 nucleotides upstream of the protease gene) and XmaI (40 nucleotides downstream of the protease gene). To produce M1, a viral DNA fragment containing the Gag and PR genes was amplified from the selected isolate using the above RT-PCR protocol in the presence of primers BssHII-for and XmaI-rev. Two additional fragments were amplified by RT-PCR, one spanning the region of Gag from BssHII to MluI restriction sites (M2) and the other spanning the PR gene from MluI to XmaI restriction sites (M3). Further segmentation of the Gag gene was performed by subcloning smaller Gag fragments from M2 into wild-type pLAI.2 using internal unique restriction sites: BssHII ϩ AgeI (M4), AgeI ϩ ApaI (M5), and ApaI ϩ XmaI (M6). When the first six constructs were tested in phenotypic assays, those which showed reduced susceptibility of Ͼ3-fold were further dissected into single or closely clustered double/triple mutants (designated M7-11). These mutations were introduced by synthesizing corresponding DNA fragments that were further subcloned into the WT pLAI.2 construct using BssHII-AgeI (MA-K112M, K113E, V128I; CA-M200I) or ApaI-XmaI (pol-D437N, L441P) restriction sites.
Plasmid DNA was purified using QIAamp DNA MiniPrep kit (Qiagen), and the sequences of cloned fragments were confirmed. Fulllength mutant clones were transfected either into HEK293T cells (American Type Culture Collection, Manassas, VA) or MT-2 cells using TransIT-LT1 reagent (Mirus Bio, Madison, WI) or Lipofectamine 2000 (Invitrogen, Carlsbad, CA). Recombinant viruses were harvested 2 to 5 days after the transfection and characterized by the content of p24 antigen using a p24 ELISA kit (Beckman Coulter, Brea, CA) and by titration for the infectivity in MT-2 cells.
Phenotypic drug susceptibility assay. The susceptibility of the PIselected HIV variants and the recombinant strains to PIs was determined Resistance to HIV-1 Protease Inhibitor GS-8374 using a cytoprotection assay in infected MT-2 cells. Fivefold serial dilutions of tested PIs were prepared in triplicate in 96-well plates in a volume of 100 l/well. MT-2 cells were infected in bulk with either the wild-type virus or each of the mutant viruses for 2 to 3 h at 37°C. Suspension of infected cells (100 l/well) was added to the assay plates containing prediluted compounds at a final cell density of 15,000/well. After a 5-day incubation at 37°C, the virus-induced CPE was determined using a cell viability assay. A 100-l portion of the medium was removed from each well and replaced with 100 l of phosphate-buffered saline containing 1.7 mg of XTT [2,3-bis(methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide; Sigma]/ml and 5 g of PMS (phenazine methosulfate; Sigma)/ml. The plates were incubated for 1 h at 37°C, followed by the addition of 20 l of 2% Triton X-100 and reading of the plate absorbance at 450 nm with a background subtraction at 650 nm. In some assays, CellTiter-Glo (Promega, Madison, WI) was used as a cell viability substrate instead of XTT. To perform the CellTiter-Glo assay, 100 l of medium was removed at the end of 5-day incubation from each well and replaced by the same volume of CellTiter-Glo reagent. The plates were incubated for 10 min at room temperature and scanned for luminescence on a Victor 3 multilabel counter (model 1420-033; Perkin-Elmer, Shelton, CT). The data were plotted as the cell viability versus the drug concentration. Cell viability was expressed as a percentage of the signal from samples with fully suppressed virus replication (treated with 300 M tenofovir) after the subtraction of signal from untreated infected cells. The concentration of each drug that inhibited the virus-induced CPE by 50% (EC 50 ) was determined by nonlinear regression using Excel and XLfit4 software (IDBS, Guildford, United Kingdom). At least three independent EC 50 determinations were conducted with each compound and each tested viral strain. Mutant viruses were always tested in parallel with a matching wild-type control. Results are presented as the mean EC 50 Ϯ the standard deviation and, for each tested mutant virus, the fold change in the mean EC 50 relative to the control wild-type virus was calculated.
Analysis of Gag proteolytic processing. HEK293T cells were transfected with the respective plasmids using the calcium phosphate method in six-well plates using 2 g of DNA per well. The medium was changed 6 h after transfection, and the cells and particles were harvested 48 h after transfection. Particles were recovered from clarified culture medium by centrifugation for 1 h at 44,000 rpm through a 20% sucrose cushion in a TLA45 rotor. Cell and particle lysates were separated either on 12.5% standard polyacrylamide gels or on 14% acrylamide Tricine gels for superior resolution of smaller proteins. Proteins were transferred to an Immobilon FL (Millipore, Billerica, MA) membrane and reacted either with a mixture of polyclonal rabbit anti-CA (1:5,000) and goat anti-NC (1:3,000; kindly provided by J. Lifson, National Cancer Institute) or with polyclonal rabbit anti-MA (1:2,000), followed by a mixture of donkey anti-rabbit IRdye700CW (LI-COR, Lincoln, NE) at 1:20,000 and donkey anti-goat IRdye800CW (LI-COR) at 1:20,000. Blots were scanned using the LI-COR Odyssey infrared imaging system and quantified with the LI-COR software as specified by the manufacturer.
Effect of Gag mutations on HIV replication fitness. Recombinant wild-type and mutant (M1 and M2) strains of HIV-1 were produced in parallel by transfecting proviral DNA in HEK293T cells as described above. Supernatants were harvested 48 h after transfection, and the p24 content was quantified by enzyme-linked immunosorbent assay (ELISA; Promega). MT2 cells were infected with a normalized virus input of 1 or 4 ng of p24 per million cells. The progression of infection was monitored by determining the p24 levels in cell culture supernatants over the course of 9 days using a p24 ELISA.
RESULTS
In vitro resistance selection. To select for an HIV variant displaying resistance to GS-8374, HIV-1 (IIIB) replicating in MT-2 cells was exposed to increasing concentrations of the inhibitor. Control resistance selection experiments were performed in parallel using atazanavir (ATV) and lopinavir (LPV). During the initial phase of the selection process, the concentration of all three drugs could be increased relatively quickly over the course of few passages. However, when a concentration of 24 nM GS-8374 was reached (8-fold above the inhibitor EC 50 ), multiple attempts to further increase GS-8374 concentration Ͼ1.3-fold failed due to a complete inhibition of virus replication in the following passages. We found that subsequent selection in the presence of GS-8374 required slow increase of the drug concentration in small increments, compared to a significantly faster progression of resistance selection with both control PIs. As summarized in Fig. 2 , the final concentration of GS-8374 reached after more than 10 months in culture was only 80 nM (26-fold above EC 50 ). In contrast, the selections with LPV and ATV reached concentrations of 2,000 nM (666-fold above EC 50 ) and 800 nM (400-fold above EC 50 ), respectively, after less than 6 months in culture.
Genotypic analysis of drug-selected HIV variants. Viruses selected in the presence of LPV and ATV were collected for analysis after 31 and 36 passages, respectively. The selected HIV variants are referred to as LPV-P31 and ATV-P36. Virus isolates selected in the presence of GS-8374 were collected at passage 36 (8374-P36), passage 47 (8374-P47), and the final passage 62 (8374-P62). Genotypic analysis of the entire PR coding region (codons 1 to 99) was performed on all collected isolates and compared to the sequence of virus cultured in parallel in the absence of any inhibitor. Population sequencing of RT-PCR-amplified viral genomes identified multiple mutations in the PR coding region of viruses selected by LPV and ATV, respectively (Table 1) . ATV-P36 contained the I50L and N88S mutations in PR, both of which have been reported to be selected in vitro and in vivo in the presence of ATV (29, 30) . Additional PR mutations detected in the ATV-P36 isolate included L10F, A71V, and V77I; all of these represent common accessory mutations present in PI-resistant isolates (Stanford HIV Drug Resistance Database [http//hivdb.stanford.edu]). The LPV-P31 virus contained PR mutations L10F, M46I, I54V, and V82A, representing one of the major pathways for LPV resistance development in vitro and in vivo (31) .
In contrast to ATV-and LPV-selected viruses, no mutations in PR were detected at passage 36 in the HIV variant selected by GS-8374. Therefore, the GS-8374 selection was sustained for an additional 26 passages. Genotypic analysis by population se- quencing of the RT-PCR-amplified viral cDNA at passage 47 revealed an emerging mutation at PR residue R41, with a mixed population of R41 (WT) and an R41K mutation. After the final passage 62, R41K had emerged as the predominant PR genotype (Table 1 ). This mutation is classified as a polymorphism (32, 33) but has not been described as a PI resistance mutation (34), suggesting that it may not be responsible for the observed resistance. We therefore performed further genotypic analysis covering the Gag open reading frame using virus from passages 36, 47, and 62 of the GS-8374-selected isolates. Comparison with the corresponding sequences of the control virus cultured in the absence of drug revealed mutations accumulating in Gag with increasing number of passages in the presence of GS-8374, whereas a substantially lower number of different mutations was detected in the control virus samples not subjected to the drug selection pressure ( Table 2 ). The observed mutations at passage 36 in the presence of GS-8374 included K113E in MA and M200I in CA, as well as a three-residue deletion ⌬NFR382-384, together with I401T and R409K mutations in the NC domain. By passage 47, an additional mutation (H219P) emerged in CA along with mutation D437N located in the transframe peptide (TFP) of Gag-Pol. Finally, several additional mutations in MA (K112M and V128I) and SP2 (Y441H) of Gag were selected by passage 62 under the pressure of GS-8374. The SP2 mutation also resulted in an amino acid substitution L441P in the overlapping p6* region of Gag-Pol (Table 2 and Fig. 3A) . It should also be noted that the mutations at positions 437 and 441 affected the nucleotide sequence of the RNA hairpin controlling the Gag-Pol translational frameshift (35) (Fig.  3B) . In comparison, the control virus accumulated only three mutations in Gag (E12K in MA, H219Q in CA, and A402S in NC) and no mutations in PR by passage 62. None of these mutations were detected in virus isolates from the GS-8374 selection (Table 2) .
To further confirm the genotype of the resistant virus selected in the presence of GS-8374, we performed clonal sequencing of the Gag and PR regions. Twenty-two clones of Gag and PR fragments derived from the 8374-P62 isolate were analyzed, and 21 of these contained the predominant Gag and PR mutations identified by population sequencing of the 8374-P62 virus (see Table S2 in the supplemental material). Two additional low-prevalence Gag mutations (K162R and H400R) were found in 7 of 22 analyzed clones.
Phenotypic analysis of drug-selected HIV variants. The isolates selected in the presence of PIs were analyzed in tissue culture for changes in their susceptibility to the selecting inhibitor, as well as other PIs, and compared to the control virus. LPV-P31 displayed 40-fold resistance to LPV while remaining susceptible to ATV, darunavir (DRV), and GS-8374 (Table 3) . Similarly, the ATV-P36 isolate was highly resistant to ATV but maintained its susceptibility to LPV, DRV, and GS-8374.
GS-8374-selected isolates from passages 36, 47 and 62, respectively, along with the control virus passaged in the absence of the drug, were tested for susceptibility against an extended panel of clinically relevant PIs. HIV-1 cultured in the presence of GS-8374 became less susceptible to the inhibitor with increasing passage number under selection pressure, showing 3.5-, 9.5-, and 14.1-fold resistances to GS-8374 at passages 36, 47, and 62, respectively (Table 4) . Low-level cross-resistance (2-to 5-fold) of the final isolate 8374-P62 was observed against several other PIs, including DRV, ATV, and saquinavir (SQV). We did not detect cross-resistance of the 8374-P62 virus against amprenavir (APV) or nelfinavir (NFV). As expected, none of the isolates selected in the presence of any of the PIs used here showed cross-resistance to the nucleoside reverse transcriptase inhibitor AZT.
To dissect the functional role of the individual Gag and PR mutations with respect to GS-8374 resistance, we constructed and characterized a panel of recombinant mutant viruses carrying subsets of the observed mutations. Recombinant virus genomes contained different fragments of Gag and/or PR coding sequences derived from the 8374-P62 isolate, thereby separating clusters of mutations residing in individual domains of Gag and Gag-PR. A total of 11 recombinant viruses with different patterns of mutations were constructed and designated M1 to M11 (Fig. 4) . M1 contained the full-length Gag-PR from the 8374-P62 isolate. M2 and M3 dissected the Gag-PR region into Gag-and PR-specific mutations, respectively. In agreement with results obtained with the 8374-P62 isolate, M1 showed a Ͼ10-fold resistance to GS- None  WT-P62  LPV  31  143  2,000  L10F, M46I, I54V, V82A  LPV-P31  ATV  36  171  800  L10F, I50L, A71V, V77I, N88S  ATV-P36  GS-8374  62  314  80  R41K  8374-P62 a That is, the amino acid changes in the protease gene (amino acids 1 to 99) relative to the sequence of wild-type HIV-1, clone HXB2 (GenBank accession no. K03455). b NA, not applicable. 8374 and a low-level cross-resistance to DRV, ATV, and LPV (7.3-, 4.3-, and 3.4-fold, respectively; Table 5 ). The profile of M3 indicated that the PR mutation R41K by itself did not confer any resistance to GS-8374 or the other tested PIs. In contrast, M2 that contained all observed Gag mutations combined with a wild-type PR sequence showed an ϳ6-fold resistance to GS-8374, together with a minor shift in the susceptibility to DRV, ATV, and LPV. The slightly weaker resistance phenotype of M2 compared to M1 suggests a synergistic effect of the mutated Gag and the R41K polymorphism in PR on the overall degree of resistance of the GS-8374-selected virus. Further dissection of Gag-PR into MA-CA, SP1-NC, and the region encoding the C-terminal segment of NC, SP2, and p6 (in the Gag reading frame), as well as TFP, p6*, and PR in the overlapping Pol reading frame, demonstrated that the MA-CA and the C-terminal Gag mutations (M4 and M6 recombinants, respectively) conferred low-level resistance to GS-8374, together with a minor cross-resistance to DRV and ATV, a phenotype qualitatively similar to that of both the original GS-8374 -P62 isolate and the M1 and M2 recombinants. In contrast, M5 carrying two NC mutations did not exhibit any changes in the susceptibility to any of the tested PIs. Further dissection of the MA-CA and the N-terminal Gag regions (recombinants M7 to M11) did not yield any virus with significantly reduced susceptibility to GS-8374 or any other tested PIs (Table 5) . Taken together, these data indicate that a combination of multiple mutations in different domains of Gag but not the R41K mutation in PR caused the reduced susceptibility to GS-8374 and a low-level cross-resistance to some of the clinically used PIs. Clusters of mutations selected in the MA-CA domain and the N-terminal part of Gag exerted a concerted effect on the susceptibility of the selected variant to GS-8374 and several other PIs. 
Mechanism of GS-8374 resistance.
Previous studies have demonstrated that Gag mutations in resistant viruses can affect the efficiency of Gag proteolytic processing in the presence of PIs (25) . To assess whether more effective cleavage of mutant Gag in the presence of GS-8374 can explain the observed resistance, we determined the efficiency of Gag processing in viruses containing various groups of mutations selected by GS-8374. Mutants M1 to M6, together with the wild-type HIV-1 IIIB virus, were produced from cells grown in the absence of drug or in the presence of 50 and 100 nM GS-8374. Virus particles were purified from tissue culture supernatants and analyzed by quantitative immunoblotting for the presence of MA-, CA-, and NC-containing Gag products. In the absence of GS-8374, the processing of mutant Gag polyproteins to fully mature individual Gag domains occurred either with similar efficiency (MA) or was somewhat reduced (CA and NC) relative to the wild-type virus ( Fig. 5; see Fig. S1 in the supplemental material). In contrast, while dose-dependent inhibition of Gag processing by GS-8374 was observed in all cases, substantially higher proportions of fully mature Gag products were present in some of the mutants compared to wild-type virus when the viruses were produced in the presence of compound. The analysis revealed a good correlation between the phenotypic resistance to GS-8374 and the efficiency of Gag processing in the presence of the inhibitor. This correlation was most obvious for the processing of CA and NC and appeared less pronounced for MA processing (Fig. 5 ). M1 and M2, which carry the complete set of mutations within Gag and exhibited the highest degree of GS-8374 resistance in the virus replication assay (11-and 6-fold, respectively), also displayed the highest resistance to GS-8374 inhibition with respect to the processing of Gag to fully mature products. Recombinant isolates M4 and M6, which had shown a lower level of resistance to GS-8374 (3.6-and 3.5-fold, respectively), also displayed an intermediate phenotype with regard to the inhibition of Gag processing. Finally, mutants M3 and M5, which did not exhibit any GS-8374 resistance, showed similar inhibition of Gag proteolysis by GS-8374 as was observed for the wild-type virus.
In addition to effects on Gag proteolytic processing, we tested whether the selected resistance mutations influence the replication capacity of HIV in the absence of GS-8374. When tested in MT-2 cells, both the M1 and M2 recombinant mutants exhibited reduced viral replication relative to the corresponding wild-type strain (see Fig. S2 in the supplemental material). These data argue against the possibility that the Gag mutations would result in an increase of the overall virus replication capacity, thereby conferring resistance to the tested PIs. Notably, the replication kinetics of the M1 strain were almost identical to those of the M2 mutant, indicating that the R41K mutation in PR does not directly compensate for the attenuated growth phenotype conferred by the selected Gag mutations.
Together, these results indicate that the mutations selected in multiple domains of Gag under GS-8374 selection pressure act in concert to confer the resistance phenotype by increasing the overall efficiency of Gag proteolytic processing in the presence of inhibitor.
DISCUSSION
In this study we have investigated antiviral resistance development against GS-8374, a representative agent from the class of phosphonate-containing HIV-1 PIs (28). We found that the development of in vitro resistance against this inhibitor was slow compared to other PIs. More than 10 months of virus passaging with gradually increasing inhibitor concentrations yielded an HIV-1 variant with only a moderately reduced susceptibility to GS-8374, indicating a high genetic barrier to resistance development. The selected virus isolate exhibited an ϳ15-fold-reduced susceptibility to GS-8374 and a 2-to 5-fold cross-resistance to several clinically relevant PIs, including DRV, ATV, and LPV, whereas no resistance was observed against other PIs. In contrast to resistant variants selected in parallel using LPV or ATV, selected GS-8374-resistant variants lacked mutations in the PR region previously associated with PI resistance. The only mutation emerging within PR was R41K, which represents a known PR sequence polymorphism; R41 and K41 are approximately equally distributed among HIV-1 variants from drug-naive patients (http://hivdb.stanford.edu). The population frequency of R41K is not increased among viruses from PI-experienced patients, indicating that R41K does not provide any selective advantage for the virus upon exposure to clinically Fig. 4) were produced by transfection of proviral DNA into 293T cells in the absence or presence of GS-8374, and the products of Gag maturation were analyzed by quantitative immunoblot (LI-COR) using polyclonal antisera raised against recombinant HIV-1 MA, CA, and NC, respectively (see Fig. S1 in the supplemental material). The band intensities were quantitated using LiCor Odyssey 2.0 software. The relative amounts of mature MA, CA, and NC products are expressed as a percentage of total Gag-derived species. The data were derived from Fig. S1 in the supplemental material.
used PIs. Consistent with this observation, our analyses did not reveal any change in susceptibility against GS-8374 when this mutation alone was introduced into a recombinant viral clone. However, in the viral isolates selected by serial passages in the presence of GS-8374, this PR mutation was accompanied by a gradual accumulation of mutations distributed over several domains of the Gag and Gag-Pol coding regions, and the R41K polymorphism appeared to have a minor additive benefit in the context of these genotypic changes in Gag.
Unlike the PR R41K mutation, the mutated Gag derived directly from the in vitro selected strain conferred significant resistance to GS-8374. Dissecting the clusters of mutations within Gag by transferring smaller fragments of the Gag coding region into the wild-type background showed that a separation of mutations according to Gag domains resulted in loss of the GS-8374 resistance phenotype. The transfer of a large segment of the N-terminal portion of Gag consisting of MA and CA with a total of five mutations resulted in a moderate, 3.5-fold resistance to GS-8374. A similar low-level resistance was associated with the combination of the R41K polymorphism in PR and three mutations in the C-terminal Gag region within the TFP-p6* domain. TFP mutations controlling the frameshift efficiency may potentially confer PI resistance by enhancing the stability of the frameshift RNA hairpin that may increase the Gag-Pol synthesis, resulting in higher amounts of PR in virions. Although calculations using a CombFold program (http://www.rnasoft.ca/cgi-bin/RNAsoft /CombFold/combfold.pl) suggested a change of Ϫ2.1 kcal/mol in the free energy of frameshift RNA hairpin derived from the 8374-P62 virus (⌬G ϭ Ϫ24.1 and Ϫ26.2 kcal/mol for the wild type and 8374-P62 RNA hairpin, respectively), the phenotypic analysis of recombinants M9, M10, and M11 demonstrated that mutations in the frameshift sequence did not confer significant resistance to GS-8374 or other PIs, indicating that this phenotype is not due to increased frameshift efficiency. An alternative mechanism based on a potential reducing effect of the D437N mutation on the previously established inhibitory activity of TFP against PR (K i ϭ 98 uM; [36] ) was also considered but was again excluded since no susceptibility changes were detected for the virus containing D437N alone (M10).
The observed results therefore indicate that resistance to GS-8374 is due to the combined effects of several sequence changes distributed throughout Gag with only a minor contribution from the R41K PR polymorphism. This is different from most of the previous studies reporting Gag-associated resistance changes, where alterations contributing significantly to PI resistance were mostly traced to the C terminus of the polyprotein and mapped to the vicinity of Gag cleavage sites (26, 37) . In contrast, mutations in MA and CA selected under GS-8374 drug pressure were mostly distant from the Gag cleavage sites. Mutations K113E and M200I were previously identified in combination with other MA-CA mutations in HIV isolates selected with RO033-4649, an investigational PI with a high genetic barrier to resistance (38) . However, a direct contribution to antiviral resistance was not established in this case (5) . Additional residues in MA (R76K, Y79F, and T81A) have recently been suggested to contribute to PI resistance both in the presence and in the absence of PR mutations by affecting virus replication capacity (39) . The CA mutation H219P has previously been described to reduce cyclophilin A incorporation into virion particles (40) and may thus have emerged primarily as a consequence of the high intracellular content of cyclophilin A in MT2 cells that were used in our resistance selection experiments. On the other hand, the contribution of the C terminus of Gag and the overlapping Pol region to PI resistance is well established. For example, SP2 mutations K436E and/or I437T/V present in several viral isolates selected in vitro by RO033-4649 conferred 4-to 7-fold resistance to a panel of PIs (25) . Similar to the observations described here, these mutations modified the efficiency of Gag proteolytic processing but had no effect on the efficiency of Gag frameshift. Importantly, Nijhuis et al. also established the initial clinical relevance of the mutations in the SP2/TFP region by detecting their presence in HIV isolates both in the absence and the presence of mutations in PR (25) . This observation was supported by a subsequent study demonstrating that mutations at positions 431 and 437 are commonly found in highly PI-experienced patients and can contribute directly to PI resistance (26) . On the other hand, Larrouy et al. detected TFP-p6* mutations D437N and/or L441P in a large group of PI-naive patients (37) . Notably, the baseline prevalences of either Asp or Gln at codon 437 and of either Leu or Pro at codon 441 were relatively equal, indicating a possible polymorphism associated with these sites. This observation is consistent with our conclusion that these two TFP mutations confer no significant PI resistance on their own.
Gradual accumulation of mutations in Gag without any PI resistance mutations in PR during the prolonged in vitro selection with GS-8374 suggests a high genetic barrier for PR to escape the inhibitor pressure. This is likely a consequence of unique interactions between the phosphonate-containing PI and the target PR enzyme. Previous X-ray crystallography analysis revealed a direct exposure of the phosphonate moiety to solvent space with no obvious interactions with amino acid residues in the active site or on the protein surface (27) . The presence of the exposed phosphonate is associated with a favorable change in the inhibitor binding entropy during the interaction with PR enzymes containing various resistance mutations in the active site. This type of thermodynamic behavior, which was not found with the parent nonphosphonate scaffold fully buried in the active site, allows for an effective adaptation of the inhibitor binding mode to changes in the volume of active-site cavity caused by the resistance mutations (27) .
When tested in MT-2 cells in the absence of GS-8374, the virus containing the selected Gag mutations exhibited considerably attenuated replication capacity relative to the corresponding wildtype virus, indicating that the reduced susceptibility to GS-8374 and some of the other tested PI is not caused by overall more effective replication of the virus. In agreement with these data, the observed cumulative changes in Gag led to improved proteolysis of mutant polyproteins by wild-type PR in the presence of GS-8374 but not in the absence of the inhibitor. The degree of this effect correlated with the relative resistance of the corresponding mutant viruses. Increased maturation efficiency of mutant Gag in the presence of GS-8374 was most obvious for the processing of CA and MA domains but was somewhat less prominent for NC. The restored Gag processing appears to be the likely mechanism of the observed resistance to GS-8374 since efficient polyprotein cleavage is a prerequisite for viral infectivity. Although the underlying molecular mechanism associated with the improved processing of mutant Gag proteins in the presence of GS-8374 is not clear, it is plausible that the Gag mutations induce conformational changes affecting the accessibility of cleavage sites to PR. Structural studies of full-length Gag or larger Gag fragments have not yet been successful, largely because of the inherent flexibility of connection domains. Assuming that the presence of PIs targeting the enzyme active site limits the effective concentration of PR in virions and thus requires improved substrate accessibility (by conformational changes) or affinity (by cleavage site changes) to maintain efficient proteolysis, one would predict that the above suggested Gag-associated mechanism should be relevant for all PIs in the context of wild-type PR. However, the GS-8374-selected variant displayed 15-fold resistance against the selecting inhibitor and a lower degree of resistance against multiple other PIs but remained sensitive to APV and NFV. These differences among individual PIs are difficult to explain by the general conformationdependent accessibility of cleavage sites. In this context, an interesting inverse correlation was observed between the affinity of each tested inhibitor toward wild-type PR and the change in its activity against the GS-8374-selected Gag mutant variant (see Fig.  S3 in the supplemental material), suggesting a more complex interplay between the enzyme, the modified Gag substrate, and each individual PI.
Notably, the selection of multiple Gag mutations by GS-8374 was reproduced independently using an HIV-1 strain with M46I/ I50V PI resistance mutations in PR. It was expected that a variant resistant to GS-8374 might emerge faster in the M46I/I50V background due to the preexisting low-level resistance to GS-8374 (27) . However, after a 9-month culturing of the M46I/I50V mutant virus in the presence of GS-8374, the inhibitor concentration could have been increased only to the level comparable to that achieved at the end of the 1-year selection initiated with the wildtype virus. After 9 months, two additional mutations emerged in PR of the M46I/I50V virus (G68E and A71V), together with nine mutations in Gag (M200I, H219Q, I401T, R409K, Y441H), in Gag-Pol (L441P), and in the hairpin controlling the translational frameshift (t2099c, t2110c, and c2134t). Seven of these mutations were at the same Gag residues as those identified in the wild-type virus selection. The resulting isolate exhibited 12-fold-reduced susceptibility to GS-8374 relative to the initial isolate (data not shown). These results lend further support to the notion that GS-8374 selects preferentially for mutations in Gag over mutations in the active site of PR.
In summary, we have characterized the in vitro emergence of resistance to a phosphonate-containing PI, GS-8374, and demonstrated that the primary pathway of resistance development involves the acquisition of multiple mutations throughout Gag, with only one supporting polymorphism in PR. This is likely due to the unique binding mode of this inhibitor to the PR active site that allows for an effective inhibition of a broad spectrum of PIresistant HIV variants, including those with common PR resistance mutations (16) . The slow emergence of resistance through the nontraditional pathway described here, together with potent activity against multi-PI resistant strains, makes the phosphonatecontaining PIs attractive candidates for antiretroviral therapy. Although the suboptimal pharmacokinetic profile in humans became limiting for the clinical development of GS-8374, the compound established a new type of resistance profile among currently known PIs and validated the phosphonate grafting strategy as a new paradigm in the design of advanced HIV PIs.
